Qiagen said this week that GE Healthcare subsidiary Clarient will offer Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
Trovagene said today that it has entered into a collaboration with the University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.
Momentum from the 2011 launch of two highly anticipated personalized medicine cancer treatments — Pfizer's Xalkori and Roche's Zelboraf — continued to spur pharmaceutical companies and test makers to engage in drug and diagnostic codevelopment collaborations throughout 2012.
Trovagene this week said that it has completed development of its first molecular diagnostic, a transrenal assay for detecting KRAS mutations, and expects to transfer the assay to its CLIA lab next month and offer the test commercially in January.
Transgenomic has been awarded a Phase I Small Business Technology Transfer grant from the National Institutes of Health to conduct initial studies on the feasibility of using Ice-Cold-PCR for the early detection of pancreatic cancer.